Description
Product Overview
KPV is a tripeptide supplied by PeptaCo for qualified laboratory research. It consists of the sequence Lysine-Proline-Valine and is derived from alpha-melanocyte-stimulating hormone (α-MSH). KPV is widely referenced in inflammation research, immune modulation studies, and peptide biology investigations.
Key Product Details
- Product Name: KPV
- Specification: 10mg per vial
- Product Form: Lyophilized powder
- Category: Immune Research Peptides
- Peptide Sequence: Lys-Pro-Val
Chemical Identity
KPV is a C-terminal fragment of α-MSH (amino acids 17-19) with the sequence Lysine-Proline-Valine. Molecular Formula: C₁₆H₂₉N₅O₄. Molecular Weight: ~339 Da. PubChem CID: 121882. This listing covers the 10mg specification under catalog number KP5.
Research Context
KPV is extensively studied in inflammation research for its role in NF-κB pathway modulation and cytokine regulation. It is commonly referenced in investigations of immune response, gut inflammation, and peptide-mediated inflammatory processes. PeptaCo supplies KPV in high-purity format for qualified laboratory customers.
Storage and Handling
Store in a cool, dry place away from direct light. Follow batch-specific storage instructions provided with the certificate of analysis. Avoid repeated freeze-thaw cycles. Handle using standard laboratory practices.
Documentation and Quality
Batch-specific analytical documentation is available to qualified customers upon request. Contact PeptaCo with the product SKU and required quantity to request the current documentation package, which may include identity confirmation, purity analysis, and batch traceability records.
Important Notice
This product is supplied for qualified laboratory research and analytical applications only. It is not for human or veterinary use. Product specifications may vary by batch. Appearance, analytical results, counter-ion information, and other release specifications should be confirmed against the certificate issued for the current batch.








Reviews
There are no reviews yet.